We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Deciphera Pharmaceuticals Inc (DCPH) USD0.01

Sell:$7.70 Buy:$7.71 Change: $0.37 (4.58%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $0.37 (4.58%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $0.37 (4.58%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition, the Company is developing three clinical-stage drug candidates, which includes Vimseltinib (DCC-3014) - colony stimulating factor 1 receptor (CSF1R) Kinase Inhibition for Tenosynovial Giant Cell Tumor (TGCT), Rebastinib - TEK tyrosine kinase (TIE2) Kinase Inhibition for advanced or Metastatic Solid Tumors, and DCC-3116 - ULK Kinase Inhibition for Mutant RAS/RAF Cancers.

Contact details

200 Smith St
United States
+1 (781) 2096400

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$471.94 million
Shares in issue:
58.48 million
United States
US dollar

Key personnel

  • Steven Hoerter
    President, Chief Executive Officer, Director
  • Daniel Flynn
    Founder, Executive Vice President, Chief Scientific Officer
  • Thomas Kelly
    Chief Financial Officer, Executive Vice President, Treasurer
  • Matthew Sherman
    Executive Vice President, Chief Medical Officer
  • Daniel Martin
    Senior Vice President, Chief Commercial Officer
  • Jama Pitman
    Senior Vice President, Regulatory and Quality Assurance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.